Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Decision Diagnostics Corp (DECN) Message Board

The annual report should be posted by March 30th (

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 11803
(Total Views: 446)
Posted On: 03/08/2018 5:10:15 PM
Posted By: DirkEaston
Re: plutonium #4205
The annual report should be posted by March 30th (Friday) as it has been in years past. That may very well be the next release of information unless something important pops up between now and then.

Below is a timeline from the latest PR. Since all of these items are in the works, I agree, there will be a lot to say.

#January 15, 2018: global introduction of the GenSure!™ test strip.

#January 28, 2018: the company intends to finalize its testing of the
GenPrecis!™ test strip.

#February 28, 2018: the company intends to finalize its testing of the
GenPrecis!™ Precise meter.

#Late February 2018 : filing of 510K application filing for GenChoice! test
strip for market clearance with the U.S. FDA.

#March 2018 : International sales of GenChoice!™ are expected to begin.

#Private Label Updates:

"We have registered with the U.S. USPTO and the U.S. FDA two new product family names; Alltara!™ and Advant!™. These brands will become those licensed to big box retailers as their own exclusive private label. We anticipate registering more trade family names as our "big box" plan proceeds. The company is currently completing the private label packaging for the GenUltimate!™ product, now named Alltara!™ ultimate. This expansion is expected to be followed by Alltara!™ choice and then by Alltara!™ precis. First deliveries of Alltara!™ ultimate are expected in 2Q 2018. This brand will not be sold by any direct to patient distributors. First postings of product images, with disclaimers, if any, will be placed on the company's websites in coming days. The company will provide a full discussion of this business model in its 2017 Annual Report."


(2)
(0)




Decision Diagnostics Corp (DECN) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us